Teva announces final approval of Venlafaxine HCl tablets

By Lisa Kerner

Charlotte, N.C., Aug. 4 - Teva Pharmaceutical Industries Ltd. said the Food and Drug Administration granted final approval for the company's abbreviated New Drug Application for Venlafaxine Hydrochloride tablets, 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg.

Shipment of the AB-rated generic equivalent of Wyeth's Effexor tablets for the treatment of major depressive disorder will begin immediately, according to a company news release.

The brand product has annual sales of about $152 million.

Teva is a generic pharmaceutical company based in Jerusalem, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.